113 related articles for article (PubMed ID: 10375743)
1. Menadione reduced doxorubicin resistance in Ehrlich ascites carcinoma cells in vitro.
Xu CJ; Zhang Y; Wang J; Zhang TM
Zhongguo Yao Li Xue Bao; 1998 May; 19(3):273-6. PubMed ID: 10375743
[TBL] [Abstract][Full Text] [Related]
2. The role of a novel copper complex in overcoming doxorubicin resistance in Ehrlich ascites carcinoma cells in vivo.
Majumder S; Dutta P; Mookerjee A; Choudhuri SK
Chem Biol Interact; 2006 Feb; 159(2):90-103. PubMed ID: 16289015
[TBL] [Abstract][Full Text] [Related]
3. [The correlation between multidrug resistance and glutathione (GSH) in EAC, EAC/ADR and EAC/ADR(R) cell lines].
Wang QD; Li GD; Liu MJ; Zhang Y; Liu J; Zhang TM
Yao Xue Xue Bao; 1994; 29(1):20-3. PubMed ID: 8036896
[TBL] [Abstract][Full Text] [Related]
4. [Reversal of adriamycin resistance by verapamil and ligustrazini in mouse Ehrlich ascites cancer].
Hu YP; Lin J; Wang QD; Yie QX; Zhang TM
Yao Xue Xue Bao; 1993; 28(1):75-8. PubMed ID: 8328276
[TBL] [Abstract][Full Text] [Related]
5. Synergistic effect of probimane on anticancer cytotoxicity of doxorubicin in vitro.
Zhang Y; Ye QX; Liu J; Zhang ZY; Zhang TM
Zhongguo Yao Li Xue Bao; 1994 Jan; 15(1):56-9. PubMed ID: 8010087
[TBL] [Abstract][Full Text] [Related]
6. Reversal of resistance against doxorubicin by a newly developed compound, oxalyl bis(N-phenyl)hydroxamic acid in vitro.
Choudhuri SK; Chatterjee A
Anticancer Drugs; 1998 Oct; 9(9):825-32. PubMed ID: 9840730
[TBL] [Abstract][Full Text] [Related]
7. Effect of doxorubicin on glutathione and glutathione-dependent enzymes in cultured rat heart cells.
Paranka NS; Dorr RT
Anticancer Res; 1994; 14(5A):2047-52. PubMed ID: 7847848
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of apoptosis is the cause of resistance to doxorubicin in human breast adenocarcinoma cells.
Osmak M; Brozović A; Ambriović-Ristov A; Hadzija M; Pivcević B; Smital T
Neoplasma; 1998; 45(4):223-30. PubMed ID: 9890665
[TBL] [Abstract][Full Text] [Related]
9. Iron N-(2-hydroxy acetophenone) glycinate (FeNG), a non-toxic glutathione depletor circumvents doxorubicin resistance in Ehrlich ascites carcinoma cells in vivo.
Ganguly A; Chakraborty P; Banerjee K; Chatterjee S; Basu S; Sarkar A; Chatterjee M; Choudhuri SK
Biometals; 2012 Feb; 25(1):149-63. PubMed ID: 21915630
[TBL] [Abstract][Full Text] [Related]
10. Relationships between the in vitro cytotoxicity and transport characteristics of pirarubicin and doxorubicin in M5076 ovarian sarcoma cells, and comparison with those in Ehrlich ascites carcinoma cells.
Nagai K; Nagasawa K; Sadzuka Y; Tsujimoto M; Takara K; Ohnishi N; Yokoyama T; Fujimoto S
Cancer Chemother Pharmacol; 2002 Mar; 49(3):244-50. PubMed ID: 11935217
[TBL] [Abstract][Full Text] [Related]
11. Reversal effect of isotetrandrine, an isoquinoline alkaloid extracted from Caulis Mahoniae, on P-glycoprotein-mediated doxorubicin-resistance in human breast cancer (MCF-7/DOX) cells.
Wang TX; Yang XH
Yao Xue Xue Bao; 2008 May; 43(5):461-6. PubMed ID: 18717331
[TBL] [Abstract][Full Text] [Related]
12. Proanthocyanidin from grape seeds enhances doxorubicin-induced antitumor effect and reverses drug resistance in doxorubicin-resistant K562/DOX cells.
Zhang XY; Li WG; Wu YJ; Bai DC; Liu NF
Can J Physiol Pharmacol; 2005 Mar; 83(3):309-18. PubMed ID: 15870845
[TBL] [Abstract][Full Text] [Related]
13. Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil.
Wu J; Lu Y; Lee A; Pan X; Yang X; Zhao X; Lee RJ
J Pharm Pharm Sci; 2007; 10(3):350-7. PubMed ID: 17727798
[TBL] [Abstract][Full Text] [Related]
14. Overcoming drug-resistant cancer by a newly developed copper chelate through host-protective cytokine-mediated apoptosis.
Mookerjee A; Mookerjee Basu J; Dutta P; Majumder S; Bhattacharyya S; Biswas J; Pal S; Mukherjee P; Raha S; Baral RN; Das T; Efferth T; Sa G; Roy S; Choudhuri SK
Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4339-49. PubMed ID: 16857809
[TBL] [Abstract][Full Text] [Related]
15. A novel copper complex induces ROS generation in doxorubicin resistant Ehrlich ascitis carcinoma cells and increases activity of antioxidant enzymes in vital organs in vivo.
Mookerjee A; Basu JM; Majumder S; Chatterjee S; Panda GS; Dutta P; Pal S; Mukherjee P; Efferth T; Roy S; Choudhuri SK
BMC Cancer; 2006 Nov; 6():267. PubMed ID: 17107616
[TBL] [Abstract][Full Text] [Related]
16. [Changes in glutathione-S-transferase activity during induction of resistance of leukemia P 388 and Ehrlich ascitic tumor cells to doxorubicin].
Donenko FV; Kabieva AO; Borovkova NB; Moroz LV
Biull Eksp Biol Med; 1991 Aug; 112(8):188-90. PubMed ID: 1786387
[TBL] [Abstract][Full Text] [Related]
17. The antitumor effects of tetrodotoxin and/or doxorubicin on Ehrlich ascites carcinoma-bearing female mice.
El-Dayem SM; Fouda FM; Ali EH; Motelp BA
Toxicol Ind Health; 2013 Jun; 29(5):404-17. PubMed ID: 22317827
[TBL] [Abstract][Full Text] [Related]
18. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump.
Goren D; Horowitz AT; Tzemach D; Tarshish M; Zalipsky S; Gabizon A
Clin Cancer Res; 2000 May; 6(5):1949-57. PubMed ID: 10815920
[TBL] [Abstract][Full Text] [Related]
19. Membrane fluidity in Ehrlich ascites tumor cells treated with adriamycin.
Sugiyama M; Sakanashi T; Okamoto K; Chinami M; Hidaka T; Ogura R
Biotechnol Appl Biochem; 1986; 8(2-3):217-21. PubMed ID: 3741633
[TBL] [Abstract][Full Text] [Related]
20. In vitro reversal MDR of human carcinoma cell line by an antisense oligodeoxynucleotide-doxorubicin conjugate.
Ren Y; Zhan X; Wei D; Liu J
Biomed Pharmacother; 2004 Nov; 58(9):520-6. PubMed ID: 15511610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
